Integra LifeSciences (NASDAQ:IART) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings results on Tuesday. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13, FiscalAI reports. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same quarter in the previous year, the business earned $0.41 EPS. The company’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences updated its FY 2026 guidance to 2.400-2.500 EPS and its Q2 2026 guidance to 0.440-0.520 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Leadership change: Stuart Essig has resumed the CEO role (retaining Chairman) with a long-term commitment and the company added Michael McBreen as Chief Commercial Officer to sharpen commercial execution, culture, and customer focus.
• Q1 beat and updated EPS guide: Q1 revenue was $392M and adjusted EPS $0.54 (above guidance); company maintained 2026 revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS to $2.40–$2.50, citing tariff benefits and operational improvements.
• Tissue Reconstruction momentum and reimbursement positioning: Tissue Reconstruction grew ~6.4% organic (strong Integra Skin, DermaClose, PriMatrix), and management says ~90% of wound reconstruction revenue is inpatient (not impacted by new CMS outpatient skin substitute rules) with the portfolio priced to compete under the new reimbursement framework.
• Quality, supply and product returns: The Compliance Master Plan remediation is progressing with improving supply reliability and Braintree production expected by end of June, but management says the 2026 guide does not rely on meaningful contribution from products still off-market.
• Cash flow and leverage path: Q1 operating cash flow improved to $9.8M, the company expects ~+$150M in operating cash flow vs. 2025, reports net debt of $1.6B and a 4.1x leverage ratio with a plan to approach target leverage of 2.5x–3.5x by end of 2026.

Integra LifeSciences Price Performance

IART opened at $13.71 on Wednesday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The firm has a 50-day moving average of $10.11 and a 200 day moving average of $11.73. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The firm has a market cap of $1.07 billion, a P/E ratio of -2.05 and a beta of 1.08.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on IART shares. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Citigroup dropped their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and a consensus price target of $14.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new position in Integra LifeSciences in the fourth quarter valued at approximately $25,000. Osaic Holdings Inc. raised its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth $124,000. Finally, Amundi increased its holdings in Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 11,004 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — quarterly EPS of $0.54 topped consensus ~$0.41 and revenue of ~$392M exceeded estimates, showing modest growth versus year‑ago figures. Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Full‑year EPS guidance raised to $2.40–$2.50, above consensus (~$2.35), giving longer‑term earnings visibility and suggesting management expects recovery/growth later in the year. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Leadership change announced — Stuart Essig named next President & CEO and Michael McBreen appointed Chief Commercial Officer; this is material but the impact depends on execution and strategy under new leadership. Integra LifeSciences Announces Leadership Transition
• Neutral Sentiment: Investors can review management commentary and detail in the earnings call transcript and slide deck for product/segment color that could drive forward guidance revisions. Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q2 guidance came in below Street expectations — management gave Q2 EPS of $0.44–$0.52 (consensus ~$0.53) and revenue guidance $410–$425M (vs. ~$425.3M consensus), creating near‑term growth risk and the main reason for the muted/negative market reaction. Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.